Biotech Values

[DewDiligence]

Re: SNY authorized generic

I think the only potential concern for MNTA from these impressive numbers is whether SNY is concerned enough about m-enox capturing too large of a market that it has to launch an authorized generic.

Not gonna happen, IMO. If SNY were planning to launch an authorized generic in the sole-generic scenario, they would have done so already. Moreover, SNY has implicitly stated in its own press release that an AG is not in the cards (#msg-53738652).

It seems patently clear that SNY and NVS have reached a tacit understanding to divide the highly profitable US Lovenox market into roughly equal shares, just as one would expect companies to behave in a “pure” duopoly.